<![CDATA[ABSTRAK Pembiayaan kesehatan di Indonesia semakin meningkat salah satunya diabetes melitus tipe 2. Diabetes melitus tipe 2 merupakan peningkatan kadar gula darah akibat cacat dalam sekresi insulin, maka diperlukan analisis efektivitas biaya untuk memutuskan pemilihan obat yang efektif secara manfaat dan biaya. Penelitian ini bertujuan untuk mengetahui antidiabetes oral kombinasi yang paling cost-effective di RSUD Kota Madiun. Penelitian dilakukan secara retrospektif terhadap data rekam medik pasien. Pengambilan data meliputi data terapi dan biaya pengobatan. Data yang diperoleh diolah dengan analisis descriptive. Efektivitas pengobatan diukur berdasarkan penurunan gula darah sewaktu (GDS) yang mencapai target sedangkan efektivitas biaya dilihat berdasarkan nilai ACER dan ICER. Hasil penelitian menunjukkan persentase efektivitas terapi obat A (metformin glimepiride) sebesar 98% sedangkan obat B (metformin acarbose) sebesar 94%. Rata-rata total biaya antidiabetes obat A (metformin glimepiride) Rp. 4.676.823,- dan obat B Rp. 5.302.005,-. Kelompok obat A (metformin glimepiride) lebih cost-effective dengan nilai ACER sebesar Rp. 47.722,- dibandingkan obat B (metformin acarbose) sebesar Rp. 56.404,- pada pasien diabetes melitus tipe 2 rawat inap di RSUD Kota Madiun. Kesimpulan dari penelitian ini yaitu kelompok terapi A (metformin glimepiride) memiliki efektivitas terapi yang paling tinggi dengan biaya lebih rendah. Harapannya rumah sakit dapat mempertahankan anggaran obat untuk penyakit diabetes melitus tipe 2 secara efektif dan efisien. Kata kunci : Diabetes melitus tipe 2, Efektivitas Biaya, Antidiabetes Oral Kombinasi ABSTRACT Health financing in Indonesia is increasing, one of which is type 2 diabetes mellitus. Type 2 diabetes mellitus is an increase in blood sugar levels due to defects in insulin secretion, so a cost analysis is needed to decide on the selection of effective and cost effective drugs. This study aims to determine the most cost-effective combination oral antidiabetic in RSUD Kota Madiun. The study was conducted retrospectively on the patient's medical record data. Data collection includes data on therapy and treatment costs. The data obtained were processed by descriptive analysis. The effectiveness of the treatment was measured based on the decrease in blood sugar while reaching the target while the cost effectiveness was measured based on the ACER and ICER values. The results showed that the percentage of therapeutic effectiveness of drug A (metformin glimepiride) was 98%, while drug B (metformin acarbose) was 94%. The average total cost of antidiabetic drug A (metformin glimepiride) is Rp. 4,676,823, - and drug B Rp. 5.302,005,-. Drug group A (metformin glimepiride) is more cost-effective with an ACER value of Rp. 47,722,- compared to drug B (metformin acarbose) of Rp. 56,404, - in patients with type 2 diabetes mellitus hospitalized at the Madiun City Hospital. The conclusion of this study was that group A (metformin glimepiride) had the highest therapeutic effectiveness with the lowest cost. It is hoped that the hospital can maintain a drug budget for type 2 diabetes mellitus effectively and efficiently. Keywords : Type 2 diabetes mellitus, Cost Effectiveness, Combination Oral Antidiabetic]]>
Copyrights © 2021
